CoChat

Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients

Open access
Feng, Ping, Yu, De-min, Chen, Li-ming, Chang, Bao-cheng, Ji, Qiu-di, Li, Shu-ying, Zhu, Mei, Ding, Sheng-hua, Zhang, Bao-zhen, Wang, Su-li, Li, Hong-tao, Lin, Jing-na, Wang, Mao-jun, Guo, Jian-chao, Liu, Jie, Liu, Zhong-dong, Wu, Shen-tao, Yang, Ju-hong · 2015 · Acta Pharmacologica Sinica
Cited by 41

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Aim:To investigate the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.Methods:A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study. The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments. Statistical analyses were performed using SPSS software package version 11.5 for Windows.Results:Liraglutide treatment caused significant reduction of the mean body weight (from 86.61±14.09 to 79.10±13.55 kg) and waist circumference (from 101.81±13.96 to 94.29±14.17 cm), resulting in body weight lose of 5%–10% in 43.67% patients, and body weight loss above 10% in 34.06% patients, who had significant lower plasma creatinine levels. Baseline waist circumference, BMI and HOMA-IR were independently correlated with the body weight loss. Furthermore, liraglutide treatment significantly decreased HbA1c levels (from 8.66%±2.17% to 6.92%±0.95%) with HbA1c<7.0% in 35.37% patients, who had a significantly lower baseline level of HbA1c, but higher baseline levels of C peptide and glucagon. Moreover, liraglutide treatment resulted in greater body weight loss in patients with a long duration of diabetes, and better glycemic control in patients with a short duration of diabetes.Conclusion:Liraglutide significantly reduces body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Patients with apparent visceral obesity, insulin resistance and a long duration of diabetes may have greater body weight loss; whereas patients with high insulin-secreting ability, hyperglucagonemia, and short-duration diabetes may obtain better glycemic control with liraglutide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/aps.2014.136

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 41

Metadata

Authors
Feng, P., Yu, D.-M., Chen, L.-M., Chang, B.-C., Ji, Q.-D., Li, S.-Y., Zhu, M., Ding, S.-H., Zhang, B.-Z., Wang, S.-L., Li, H.-T., Lin, J.-N., Wang, M.-J., Guo, J.-C., Liu, J., Liu, Z.-D., Wu, S.-T., & Yang, J.-H.
Venue
Acta Pharmacologica Sinica
Published
2015-01-26
Volume
36
Issue
2
Pages
200-208
ISSN
  • 0253-9756 (ISSN-L)
  • 1671-4083
  • 1745-7254
OpenAlex
W2066890908
Cited by
41
References
13
FWCI
2.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. https://app.cochat.ai/papers/10.1038/aps.2014.136
The paper
Feng, P., Yu, D.-M., Chen, L.-M., Chang, B.-C., Ji, Q.-D., Li, S.-Y., Zhu, M., Ding, S.-H., Zhang, B.-Z., Wang, S.-L., Li, H.-T., Lin, J.-N., Wang, M.-J., Guo, J.-C., Liu, J., Liu, Z.-D., Wu, S.-T., & Yang, J.-H. (2015). Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Acta Pharmacologica Sinica. https://doi.org/10.1038/aps.2014.136

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.